Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.

Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D

Open source

DOI
10.1097/cad.0000000000000647
Published
2018 Sep
Container
Anti-cancer drugs
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/cad.0000000000000647,
  title = {Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.},
  author = {Wang Y and Liu Q and Chen H and You J and Peng B and Cao F and Zhang X and Chen Q and Uzan G and Xu L and Zhang D},
  year = {2018},
  journal = {Anti-cancer drugs},
  doi = {10.1097/cad.0000000000000647},
  url = {https://doi.org/10.1097/cad.0000000000000647}
}

RIS

TY  - JOUR
TI  - Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
AU  - Wang Y
AU  - Liu Q
AU  - Chen H
AU  - You J
AU  - Peng B
AU  - Cao F
AU  - Zhang X
AU  - Chen Q
AU  - Uzan G
AU  - Xu L
AU  - Zhang D
PY  - 2018
JO  - Anti-cancer drugs
DO  - 10.1097/cad.0000000000000647
UR  - https://doi.org/10.1097/cad.0000000000000647
ER  - 

APA

Y, W., Q, L., H, C., J, Y., B, P., F, C., X, Z., Q, C., G, U., L, X., & D, Z. (2018). Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.. Anti-cancer drugs. https://doi.org/10.1097/cad.0000000000000647

Source records